2024 Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician - Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Nature Reviews Rheumatology. 2024 Feb;20(2):101-15.

2023 Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. - Kerekes G, Czókolyová M, Hamar A, Pusztai A, Tajti G, Katkó M, Végh E, Pethő Z, Bodnár N, Horváth Á, Soós B. 2023 Oct 1;62(SI3):SI304-12.

2023 Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis - Kacsándi D, Fagyas M, Horváth Á, Végh E, Pusztai A, Czókolyová M, Soós B, Szabó AÁ, Hamar A, Pethő Z, Bodnár N. Frontiers in Medicine. 2023 Oct 9;10:1226760.

2022 Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the rheumatic diseases. 2022 Jan 1;81(1):20-33.

2022 Czókolyová M, Hamar A, Pusztai A, Tajti G, Végh E, Pethő Z, Bodnár N, Horváth Á, Soós B, Szamosi S, Szentpéteri A. Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis. Biomolecules. 2022 Oct 14;12(10):1483.

2021 Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, Van Der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the rheumatic diseases. 2021 Jan 1;80(1):31-5.

2021 Hamar A, Hascsi Z, Pusztai A, Czókolyová M, Végh E, Pethő Z, Gulyás K, Soós B, Kerekes G, Szekanecz É, Hodosi K. Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status. RMD open. 2021 Nov 1;7(3):e001804.

2021 Hamar A, Szekanecz Z, Pusztai A, Czókolyová M, Végh E, Pethő Z, Bodnár N, Gulyás K, Horváth Á, Soós B, Bodoki L. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporosis International. 2021 Aug;32(8):1621-9.

2021 Roodenrijs NM, Kedves M, Hamar A, Nagy G, van Laar JM, van der Heijde D, Welsing PM. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021 Jan 1;7(1):e001511.

2021 Roodenrijs NM, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, Welsing PM. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD open. 2021 Jan 1;7(1):e001512.

2021 Pusztai A, Hamar A, Czókolyová M, Gulyás K, Horváth Á, Végh E, Pethő Z, Szamosi S, Balogh E, Bodnár N, Bodoki L. Associations of vascular and bone status in arthritis patients. Scientific Reports. 2021 Sep 30;11(1):1-0.

2021 Czókolyová M, Pusztai A, Végh E, Horváth Á, Szentpéteri A, Hamar A, Szamosi S, Hodosi K, Domján A, Szántó S, Kerekes G. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. Biomolecules. 2021 Oct 18;11(10):1535.

2021 Juhász B, Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethő Z, Bodnár N, Hamar A, Bodoki L, Bhattoa HP. Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. BMC musculoskeletal disorders. 2021 Dec;22(1):1-9.

2021 Soós B, Fagyas M, Horváth Á, Végh E, Pusztai A, Czókolyová M, Csongrádi A, Hamar A, Pethő Z, Bodnár N, Kerekes G. Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients. Frontiers in medicine. 2021;8.

2020 Végh E, Kerekes G, Pusztai A, Hamar A, Szamosi S, Váncsa A, Bodoki L, Pogácsás L, Balázs F, Hodosi K, Domján A. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatology international. 2020 Mar;40(3):427-36.

2020 Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clinical rheumatology. 2020 Jan;39(1):167-75.

2019 Sarzi-Puttini P, Marotto D, Caporali R, Galeazzi M, Atzeni F, Hamar A, Soós B, Szekanecz Z. Biosimilars vs originators: Are they the same?. Autoimmunity Reviews. 2019 Dec 1;18(12):102404.

2019 Horváth Á, Végh E, Pusztai A, Pethő Z, Hamar A, Czókolyová M, Bhattoa HP, Nagy G, Juhász B, Hodosi K, Domján A. Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients. Arthritis Research & Therapy. 2019 Dec;21(1): 1-0.

2019 Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, McCormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z. Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. Clinical Immunology. 2019 Feb 1;199:47-51.

2019 Balogh E, Végh E, Kerekes G, Pusztai A, Hamar A, Hodosi K, Szamosi S, Váncsa A, Csomor P, Bodoki L, Pogácsás L. Effects of one-year anti-TNF-α therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides. Rheumatol Orthop Med. 2019 Oct 2;4:1-8.

2019 Póliska S, Besenyei T, Végh E, Hamar A, Pusztai A, Váncsa A, Bodnár N, Szamosi S, Csumita M, Kerekes G, Szabó Z. Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis. Arthritis research & therapy. 2019 Dec;21(1):1-1.

2016 Hamar A, Pusztai A, Szántó S, Szekanecz Z (2016): A tirozinkináz-gátlás lehetőségei rheumatoid arthritisben (összefoglaló közlemény). Immunológiai Szemle VIII.évfolyam 3.szám 2016.október 13-30.oldal [2016]